Complex Generics Guidance: US FDA Aims To Alert Firms, As GAO Requested
Executive Summary
The US FDA says it's working to provide the type of notice generic drug firms told the General Accountability Office they want to receive whenever the agency plans to issue or revise product-specific guidance on complex generics. Surprise issuance causes setbacks for generic drug sponsors who must scramble to revise their applications accordingly, if they can.
You may also be interested in...
FDA Looks Ahead To Complex Product-Specific Guidances
The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.
Exploring the US FDA's Upcoming Complex Generic Product-Specific Guidance Lists
The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.
Complex Generic Approval Delays Getting Congressional Attention
US Energy and Commerce Committee leaders request data on complex generic approvals, guidances, saying additional changes may be needed for faster approvals.